Compare Moderna, Inc. (MRNA) vs Norfolk Southern Corporation (NSC) Price & Performance

Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.

The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.

Norfolk Southern (NSC) trades at $334.44, up 0.15% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals, including three consecutive quarterly earnings beats, a net income margin of 21.02%, and robust cash flow from operations of $4.36B in 2025. Recent news highlights merger developments with Union Pacific and positive Q2 2026 results driven by freight demand.

Outlook is positive with a consensus price target of $369.67, implying upside, but risks include high valuation (P/E 28.55), merger regulatory scrutiny, and fuel cost pressures. Institutional sentiment is mixed with 43.75% buy ratings, yet hedge fund activity suggests potential momentum.